<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584818</url>
  </required_header>
  <id_info>
    <org_study_id>127-013</org_study_id>
    <nct_id>NCT00584818</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease</brief_title>
  <official_title>A Phase 2 Dose-Finding Clinical Trial of CARDIOsphere® (PB127) in Normal Volunteers and in Patients With Known or Suspected Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Point Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Point Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of
      coronary artery disease when used with cardiac ultrasound. This study also evaluates the
      safety of PB127.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the minimum effective dose of PB127</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the optimal stress infusion rate of PB127</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of PB127 MPE using the dose and stress infusion rate identified in Stages 1 and 2</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of PB127</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">205</enrollment>
  <condition>Healthy</condition>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB127 for Injectable Suspension</intervention_name>
    <description>Stages 1 &amp; 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.
Stage 3 - will utilize infusion rate and dose established in Stages 1 &amp; 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions.</description>
    <other_name>CARDIOsphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stages 1 and 2

          1. Men and women

          2. Ages 18 30

          3. Normal volunteers

          4. No history (or suspicion) of CAD

        Stage 3

          1. Men and women with known or suspected CAD

          2. Ages 18 years and older

          3. Scheduled for or undergone clinically indicated coronary angiography within 28 days
             prior to or following Study Day 1

               1. Coronary angiography within 28 days prior to Study Day 1 and/or SPECT must have
                  been non-interventional

               2. Coronary angiography images available in digital format (non cine) for
                  transmission to core laboratory

          4. Scheduled for or undergone SPECT within 28 days prior to or following Study Day 1

        Exclusion Criteria:

          1. Unable to provide written informed consent

          2. Women who are pregnant or lactating

          3. Known hypersensitivity or known contraindication to:

               1. Dipyridamole

               2. Ultrasound contrast agents (including PB127 and excipients)

               3. Blood, blood products, albumin, egg whites, or protein

          4. Use of caffeine or xanthine containing products within the 24 hours prior to PB127
             administration on Study Day 1 (Stages 2 and 3)

          5. Previous exposure to PB127

          6. Inadequate echocardiographic windows

          7. Heart transplant

          8. Known right to left shunt, including atrial septal defect

          9. History of CABG

         10. Current uncontrolled ventricular tachycardia, atrial fibrillation, atrial tachycardia,
             or atrial flutter

         11. Pacemaker or defibrillator

         12. Unstable angina grade CCS Class IV severity with ongoing symptoms and/or ongoing
             infusion of IV nitroglycerin

         13. Second degree or greater heart block

         14. Hypertension (SPB &gt;200 and/or DBP &gt;110 mmHg on two consecutive readings within 1 hour
             prior to PB127 administration)

         15. Hypotension (SPB &lt;90 mmHg on two consecutive readings within 1 hour prior to PB127
             administration)

         16. Severe aortic stenosis (&gt;100 mmHg peak transvalvar gradient or &lt;0.6 cm2 estimated
             valve area)

         17. Pulmonary edema within the 7 days prior to Study Day 1

         18. Resting oxygen saturation of less than 90%

         19. Q wave MI or major surgery within the 7 days prior to Study Day 1

         20. PTCA within the 28 days prior to Study Day 1

         21. Chronic obstructive pulmonary disease or bronchospastic airway disease which, in the
             opinion of the Investigator, is significant enough to contraindicate dipyridamole

         22. Known history of severe pulmonary hypertension characterized by estimated pulmonary
             artery systolic pressure of &gt;50 mmHg

         23. Liver disease, characterized by or including one or more of the following

               1. Elevated total bilirubin &gt; upper limit of normal

               2. Currently elevated hepatic enzymes &gt;3X upper limit of normal

         24. Medical conditions or other circumstances that would significantly decrease the
             chances of obtaining reliable data or achieving the study objectives (i.e., drug
             dependence, psychiatric disorder, dementia, or associated illness); extenuating
             circumstances or medical conditions that make it unlikely that a patient can complete
             the clinical trial or follow up evaluations; or other reasons for expected poor
             compliance with the clinical investigator's instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ehlgen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biomedical Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach VA Medical Center Cardiology Division</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Division of Cardiology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfieri Cardiology</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiology Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cardiovascular Studies Kramer and Crouse Cardiology</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androscoggin Cardiovascular Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Healthcare Network Brackenridge Hospital</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cardiovascular Research Institute Spokane Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tom Ottoboni PhD/Chief Operating Officer</name_title>
    <organization>POINT Biomedical Corp.</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>chest pain</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>SPECT</keyword>
  <keyword>angiogram</keyword>
  <keyword>ultrasound</keyword>
  <keyword>echocardiogram</keyword>
  <keyword>perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

